The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating cell-free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive (MI) and metastatic (met) bladder cancer (BC).
 
Jaleh Fallah
No Relationships to Disclose
 
Shinjini Ganguly
No Relationships to Disclose
 
Hong Li
No Relationships to Disclose
 
Wei (Auston) Wei
No Relationships to Disclose
 
Aysegul Balyimez
No Relationships to Disclose
 
Thirunavukkarasu Sitalaximi
No Relationships to Disclose
 
C. Marcela Diaz-Montero
No Relationships to Disclose
 
Patricia A. Rayman
No Relationships to Disclose
 
Marcelo Lamenza
No Relationships to Disclose
 
Priscilla Dann
No Relationships to Disclose
 
Donna Company
No Relationships to Disclose
 
Rahul D. Tendulkar
Honoraria - Varian Medical Systems
 
Mohamed Abazeed
No Relationships to Disclose
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Merck; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Pfizer; Sanofi
 
Moshe Chaim Ornstein
Consulting or Advisory Role - Eisai; Exelixis; Pfizer
Speakers' Bureau - Exelixis
Travel, Accommodations, Expenses - Exelixis
 
Brian I. Rini
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Byron H Lee
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Foundation Medicine; Genentech; HERON; Janssen; Merck; Pfizer; QED Therapeutics; Seagen
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Omar Y. Mian
No Relationships to Disclose